European Journal of Clinical Pharmacology

, Volume 66, Issue 10, pp 1037–1046

Clinical pharmacology consultation: a better answer to safety issues of drug therapy during pregnancy?

  • Viktorija Erdeljić
  • Igor Francetić
  • Ksenija Makar-Aušperger
  • Robert Likić
  • Matea Radačić-Aumiler
Pharmacoepidemiology and Prescription

Abstract

Purpose

Drug safety classifications give a very basic estimation of risk and should only be used as general guideline when assessing risk of pregnancy-related drug exposure or planning treatment. We conducted a study to assess the strength of association between both the clinical pharmacologists’ risk assessment and the FDA risk categorization, and adverse pregnancy outcomes.

Methods

We retrospectively reviewed records of 1,076 patients consecutively referred to the clinical pharmacology outpatient clinic for pregnancy-related drug exposure (2000–2008). Clinical pharmacologists’ risk assessments were reviewed in relation to FDA drug categorization and available pregnancy outcomes.

Results

Overall, clinical pharmacologists’ risk estimation was in agreement with the FDA risk categorization system in only 28% of consulted women, and in only 9% of women with high-risk exposure (FDA DX). Clinical pharmacologists’ risk assessment confirming high-risk drug exposure had a better positive predictive value for adverse pregnancy outcomes than the FDA DX categorization (25% vs 14% respectively), while the negative predictive values were similar (92% vs 94% respectively). Clinical pharmacologists’ risk assessment was a better predictor of adverse pregnancy outcomes compared with FDA risk categorization (OR 2.11 [95%CI 1.5-3.1; p < 0.001] vs OR 1.52 [95%CI 1.1-2.1; p = 0.014] respectively).

Conclusions

Additional evaluation beyond the FDA drug classification is essential for safer and more rational drug use in pregnancy. Clinical pharmacologists who have undergone rigorous medical training are ideally placed to consult on administration of medicines in pregnant women, thus making the prescribing of treatments in that patient category substantially safer and more rational.

Key words

Pregnancy-related drug exposure FDA Drug safety classifications Clinical pharmacology Risk assessment Drug safety 

References

  1. 1.
    Oakley GP Jr (1986) Frequency of human congenital malformations. Clin Perinatol 13:545–554PubMedGoogle Scholar
  2. 2.
    Koren G (1994) Maternal-fetal toxicology: a clinician’s guide. Dekker, New YorkGoogle Scholar
  3. 3.
    Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL (2000) Prescription of drugs during pregnancy in France. Lancet 356:1735–1736. doi:10.1016/S0140-6736(00)03209-8 CrossRefPubMedGoogle Scholar
  4. 4.
    Haramburu F, Miremont G, Moride Y, Gomez MP, Douchet P, Douet C (1995) Drug prescription during pregnancy: a cohort study. Pharmacoepidemiol Drug Saf 4:74Google Scholar
  5. 5.
    Henry A, Crowther C (2000) Patterns of medication use during, and prior to pregnancy: the MAP study. Aus NZ J Obstet Gynaecol 40:165–172CrossRefGoogle Scholar
  6. 6.
    Yang T, Walker MC, Krewski D, Yang Q, Nimrod C, Garner P, Fraser W, Olatunbosun O, Wen SW (2008) Maternal characteristics associated with pregnancy exposure to FDA category C, D, and X drugs in a Canadian population. Pharmacoepidemiol Drug Saf 17(3):270–277. doi:10.1002/pds.1538 CrossRefPubMedGoogle Scholar
  7. 7.
    Webster WS, Freeman JA (2001) Is this drug safe in pregnancy? Reprod Toxicol 15(6):619–629. doi:10.1016/S0890-6238(01)00185-X CrossRefPubMedGoogle Scholar
  8. 8.
    Boothby LA, Doering PL (2001) FDA labeling system for drugs in pregnancy. Ann Pharmacother 35(11):1485–1489CrossRefPubMedGoogle Scholar
  9. 9.
    Addis A, Magrini N, Mastroiacovo P (2001) Drug use during pregnancy. Lancet 357:800. doi:10.1016/S0140-6736(05)71221-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Addis A, Sharabi S, Bonati M (2000) Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 23(3):245–253CrossRefPubMedGoogle Scholar
  11. 11.
    Feibus KB (2008) FDA’s proposed rule for pregnancy and lactation labelling: improving maternal child health through well-informed medicine use. J Med Toxicol 4(4):284–288CrossRefPubMedGoogle Scholar
  12. 12.
    Bencarić L (2009) Registar Lijekova u Hrvatskoj. Udruga poslodavaca u zdravstvu, ZagrebGoogle Scholar
  13. 13.
    Vrhovac B et al (2007) Farmakoterapijski priručnik. Medicinska naklada, ZagrebGoogle Scholar
  14. 14.
  15. 15.
  16. 16.
    ADEC: Australian Drug Evaluation Committee (1996) Medicines in Pregnancy—an Australian categorisation of risk of drug use in pregnancy. Australian Government Publishing Service, CanberraGoogle Scholar
  17. 17.
    Widnes F, Sofia K, Schjott J (2008) Advice on drug safety in pregnancy: are there differences between commonly used sources of information? Drug Saf 31(9):799–806CrossRefGoogle Scholar
  18. 18.
    British Medical Association and Royal Pharmaceutical Society of Great Britain (2009) British National Formulary. BMJ Group and RPS Publishing, LondonGoogle Scholar
  19. 19.
    American Society of Health-System Pharmacists (2008) AHFS Drug Information. American Society of Health-System Pharmacists, BethesdaGoogle Scholar
  20. 20.
    Briggs DD (2008) Drugs in pregnancy and lactation. Lippincot Williams Wilkins, PhiladelphiaGoogle Scholar
  21. 21.
    Micromedex® Healthcare Series Vol. 144, expires 6/2010Google Scholar
  22. 22.
    www.ncbi.nlm.nih.gov/pubmed/. Accessed 2 June 2010
  23. 23.
    Sannerstedt R, Lundborg P, Danielsson BR, Kihlstrom I, Alvan G, Prame B, Ridley E (1996) Drugs during pregnancy: an issue of risk classification and information to prescribers. Drug Saf 14:69–77CrossRefPubMedGoogle Scholar
  24. 24.
    Buhimschi CS, Weiner CP (2009) Medications in pregnancy and lactation. I. Teratology. Obstet Gynecol 113(1):166–188PubMedGoogle Scholar
  25. 25.
    Lee E, Maneno MK, Smith L, Wiess SR, Zuckerman IH, Wutoh AK, Xue Z (2006) National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 15(8):537–545. doi:10.1002/pds.1241 CrossRefPubMedGoogle Scholar
  26. 26.
    Culig J, Leppee M, Stimac D, Kuvacic I, Pulanic-Klepac T, Herman R, Tuckar N, Podobnik M, Klobucar A, Matesa S, Polic-Vizintin M, Damic A (2007) Cross-sectional study of drug use in pregnancy. Lijec Vjesn 129:253–259PubMedGoogle Scholar
  27. 27.
    Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA, Fortman KK, McPhillips H, Roblin D, Smith DH, Yood MU, Platt R, Gurwitz JH (2006) Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 15(8):546–554. doi:10.1002/pds.1235 CrossRefPubMedGoogle Scholar
  28. 28.
  29. 29.
    Adams P, Hendershot G, Marano M (1999) Current estimates from the National Health Interview Survey. Vital Health Stat 10:83–84Google Scholar
  30. 30.
    Kovacić L, Gazdek D, Samardzić S (2007) Croatian health survey: cigarette smoking. Acta Med Croat 61(3):281–285Google Scholar
  31. 31.
  32. 32.
    Briggs GG, Freeman RK, Yaffe JS (2008) Drugs in pregnancy and lactation. Lippincott Williams & Willkins, PhiladelphiaGoogle Scholar
  33. 33.
  34. 34.
    Nybo Andersen AM, Wohlfart J, Christens P, Olsen J, Melbye M (2000) Maternal age and fetal loss: population based register linkage study. BMJ 320:1708–1712CrossRefPubMedGoogle Scholar
  35. 35.
    De La Rochebrochard E, Thonneau P (2002) Paternal age and maternal age are risk factors for miscarriage; results of a multicentre European study. Hum Reprod 17(6):1649–1656CrossRefPubMedGoogle Scholar
  36. 36.
  37. 37.
    Delbaere I, Verstraelen H, Goetgeluk S, Martens G, De Backer G, Temmerman M (2007) Pregnancy outcome in primiparae of advanced maternal age. Eur J Obstet Gynecol Reprod Biol 135(1):41–46. doi:10.1016/j.ejogrb.2006.10.030 CrossRefPubMedGoogle Scholar
  38. 38.
    Khairy P, Ouyang DW, Fernandes SM, Lee-Parritz A, Economy KE, Landzberg MJ (2006) Pregnancy outcomes in women with congenital heart disease. Circulation 113:517–524. doi:10.1161/CIRCULATIONAHA.105.589655 CrossRefPubMedGoogle Scholar
  39. 39.
    Meador K, Reynolds MW, Crean S, Fahrbach K, Probst C (2008) Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 81(1):1–13. doi:10.1016/j.eplepsyres.2008.04.022 CrossRefPubMedGoogle Scholar
  40. 40.
    Bai J, Wong FWS, Bauman A, Mohsin M (2002) Parity and pregnancy outcomes. Am J Obstet Gynecol 186(2):274–278. doi:10.1067/mob.2002.119639 CrossRefPubMedGoogle Scholar
  41. 41.
    Engeland A, Bramness JG, Dalveit AK, Ronning M, Skurtveit S, Furu K (2008) Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol 65(5):653–660. doi:10.1111/j.1365-2125.2008.03102.x CrossRefPubMedGoogle Scholar
  42. 42.
  43. 43.
    Samrén EB, van Duijn CM, Koch S, Hiilesmaa VK, Klepel H, Bardy AH, Mannagetta GB, Deichl AW, Gaily E, Granström ML, Meinardi H, Grobbee DE, Hofman A, Janz D, Lindhout D (1997) Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 38:981–990CrossRefPubMedGoogle Scholar
  44. 44.
    Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, Gallo C (2002) Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 99:35–40CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Viktorija Erdeljić
    • 1
  • Igor Francetić
    • 1
  • Ksenija Makar-Aušperger
    • 1
  • Robert Likić
    • 1
  • Matea Radačić-Aumiler
    • 1
  1. 1.Division of Clinical Pharmacology, Department of MedicineUniversity Hospital ZagrebZagrebCroatia

Personalised recommendations